Giulia C. Kennedy net worth and biography

Giulia Kennedy Biography and Net Worth

Insider of Veracyte
Giulia C. Kennedy is Chief Scientific and Medical Officer for Veracyte. Since joining the diagnostics company in 2008 as part of the founding team, Dr. Kennedy has overseen the development of five commercialized genomic tests that resolve diagnostic uncertainty and are becoming standard of care. Through Dr. Kennedy’s leadership, Veracyte pushes the boundaries of what is possible by using big data and machine learning to answer critical clinical questions. Prior to Veracyte, Dr. Kennedy was Senior Director of Genomics at Affymetrix, Inc.and led the transition of a novel microarray-based genotyping method from research through product development and successful commercialization.

Previously, Dr. Kennedy was a scientific leader in cancer gene discovery at Chiron Corporation. Before that, she was a scientist at Millennium Pharmaceuticals, where she implemented genetic approaches to study diabetes. She holds a Ph.D. in Biochemistry and completed postdoctoral training at UCSF, and now serves as an advisor for their Catalyst Program. She was recently appointed as a Board Director of Astarte Medical, a precision medicine company. Dr. Kennedy has published more than 70 peer-reviewed scientific articles and is a co-inventor on more than 20 patents.

What is Giulia C. Kennedy's net worth?

The estimated net worth of Giulia C. Kennedy is at least $1.76 million as of December 6th, 2022. Dr. Kennedy owns 65,970 shares of Veracyte stock worth more than $1,759,420 as of February 5th. This net worth estimate does not reflect any other assets that Dr. Kennedy may own. Learn More about Giulia C. Kennedy's net worth.

How do I contact Giulia C. Kennedy?

The corporate mailing address for Dr. Kennedy and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected] Learn More on Giulia C. Kennedy's contact information.

Has Giulia C. Kennedy been buying or selling shares of Veracyte?

Giulia C. Kennedy has not been actively trading shares of Veracyte during the last ninety days. Learn More on Giulia C. Kennedy's trading history.

Who are Veracyte's active insiders?

Veracyte's insider roster includes Bonnie Anderson (Insider), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Giulia Kennedy (Insider), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.

Are insiders buying or selling shares of Veracyte?

In the last year, Veracyte insiders bought shares 1 times. They purchased a total of 60,000 shares worth more than $979,800.00. In the last year, insiders at the biotechnology company sold shares 10 times. They sold a total of 218,685 shares worth more than $5,751,665.81. The most recent insider tranaction occured on January, 17th when Director Bonnie H Anderson sold 34,000 shares worth more than $895,900.00. Insiders at Veracyte own 2.9% of the company. Learn More about insider trades at Veracyte.

Information on this page was last updated on 1/17/2023.

Giulia C. Kennedy Insider Trading History at Veracyte

See Full Table

Giulia C. Kennedy Buying and Selling Activity at Veracyte

This chart shows Giulia C. Kennedy's buying and selling at Veracyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veracyte Company Overview

Veracyte logo
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Read More

Today's Range

Now: $26.67
Low: $25.80
High: $27.52

50 Day Range

MA: $25.90
Low: $22.39
High: $29.80

2 Week Range

Now: $26.67
Low: $14.85
High: $33.23

Volume

551,822 shs

Average Volume

640,734 shs

Market Capitalization

$1.91 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45